Pouch-ouch

Current Opinion in Gastroenterology

Volumn 24, Issue 1, 2008, Pages 70-74

  Maser, Elana A ^a,b   Present, Daniel H ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Pouchitis; Risk factors; Surveillance; Therapy

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CYCLOSPORIN; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; TINIDAZOLE;

ANTIBIOTIC THERAPY; CANCER EPIDEMIOLOGY; DIFFERENTIAL DIAGNOSIS; DYSGEUSIA; HUMAN; ILEITIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; REVIEW; RISK FACTOR; ULCERATIVE COLITIS;

ALGORITHMS; COLECTOMY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MONITORING, PHYSIOLOGIC; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 36549045193     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f2dfa3     Document Type: Review

References (33)

1. Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol 2006; 40:669-677.
2. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845.
3. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587-1592.
4. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54:960-965.
5. Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 2007; 5:352-360.
6. M'koma AE, Wise PE, Muldoon RL, et al. Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones. Int J Colorectal Dis 2007; 22:1143-1163.
7. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouchanal anastomosis. Gut 2001; 49:671-677.
8. Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol 2003; 38:1055-1058.
9. Aitola P, Matikainen M, Mattila J, et al. Chronic inflammatory changes in the pouch mucosa are associated with cholangitis found on peroperative liver biopsy specimens at restorative proctocolectomy for ulcerative colitis. Scand J Gastroenterol 1998; 33:289-293.
10. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38:234-239.
11. Shen B, Fazio VW, Remzi FH, et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig Dis Sci 2007; 5 April [Epub ahead of print].
12. Fleshner P, Ippoliti A, Dubinsky M, et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007; 5:952-958. This is an important paper that identifies risk factors for acute and chronic pouchitis separately. This is achieved by using multivariate analysis.
13. Nakamura M, Ikeuchi H, Nakano H, et al. Postoperative joint symptoms: a risk factor for pouchitis in ulcerative colitis patients. Dig Surg 2006; 23:60-64.
14. Shen B, Fazio VW, Remzi FH, et al. Risk factors for diseases of ileal pouchanal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:81-89. This study, performed by experts in the field, highlights risk factors for all the various diseases that can affect a pouch. It is not limited to pouchitis.
15. Millan M, Hull TL, Hammel J, Remzi F. Portal vein thrombi after restorative proctocolectomy: serious complication without long-term sequelae. Dis Colon Rectum 2007; 16 August [Epub ahead of print].
16. Schmidt C, Hauser W, Giese T, Stallmach A. Irritable pouch syndrome is associated with depressiveness and can be differentiated from pouchitis by quantification of mucosal levels of proinflammatory gene transcripts. Inflamm Bowel Dis 2007; 21 August [Epub ahead of print].
17. Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 2004; 126:1280-1286.
18. Lundberg JO, Hellstrom PM, Fagerhol MK, et al. Technology insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2:96-102.
19. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124:1202-1209.
20. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39:1193-1196.
21. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
22. Fiocchi C. Probiotics in inflammatory bowel disease: yet another mechanism of action? Gastroenterology 2006; 131:2009-2012.
23. Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. Aliment Pharmacol Ther 2006; 23:1087-1096. An excellent comprehensive systematic review of the management of pouchitis.
24. Isaacs KL, Sandler RS, Abreu M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13 June [Epub ahead of print].
25. Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007; 50:498-508.
26. Shen B, Goldblum JR, Hull TL, et al. Clostridium difficile-associated pouchitis. Dig Dis Sci 2006; 51:2361-2364.
27. Gionchetti P, Rizzello F, Poggioli G, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007; 25:1231-1236. This paper, published by the leaders in probiotic use for the prevention of pouchitis, highlights oral budesonide as a novel therapy for the treatment of pouchitis.
28. Gullichsen R. Long-acting octreotide in the treatment of diarrhea after pelvic pouch surgery. Tech Coloproctol 2006; 10:346-349.
29. Heppell J, Weiland LH, Perrault J, et al. Fate of the rectal mucosa after rectal mucosectomy and ileoanal anastomosis. Dis Colon Rectum 1983; 26:768-771.
30. Das P, Johnson MW, Tekkis PP, Nicholls RJ. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2007; 9:15-27. The authors review the rationale for screening patients for the development of adenocarcinoma following IPAA.
31. Herline AJ, Meisinger LL, Rusin LC, et al. Is routine pouch surveillance for dysplasia indicated for ileoanal pouches? Dis Colon Rectum 2003; 46:156-159.
32. Schaus BJ, Fazio VW, Remzi FH, et al. Clinical features of ileal pouch polyps in patients with underlying ulcerative colitis. Dis Colon Rectum 2007; 50:832-838.
33. Gullberg K, Stahlberg D, Liljeqvist L, et al. Neoplastic transformation of the pelvic pouch mucosa in patients with ulcerative colitis. Gastroenterology 1997; 112:1487-1492.